IXIARO SUSPENSION

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

INACT.JAPANESE ENCEPHAL VIRUS(ATTENUAT. STRAIN SA14-14-2 PRODUCED IN VERO CELLS)

Fáanlegur frá:

VALNEVA AUSTRIA GMBH

ATC númer:

J07BA02

INN (Alþjóðlegt nafn):

ENCEPHALITIS, JAPANESE, INACTIVATED, WHOLE VIRUS

Skammtar:

6MCG

Lyfjaform:

SUSPENSION

Samsetning:

INACT.JAPANESE ENCEPHAL VIRUS(ATTENUAT. STRAIN SA14-14-2 PRODUCED IN VERO CELLS) 6MCG

Stjórnsýsluleið:

INTRAMUSCULAR

Einingar í pakka:

0.5ML

Gerð lyfseðils:

Schedule D

Lækningarsvæði:

VACCINES

Vörulýsing:

Active ingredient group (AIG) number: 0152652001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2013-10-08

Vara einkenni

_ _
_Appendix I - Product Monograph Template - Schedule D _
_Page 1 of 57_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
IXIARO
*
Japanese encephalitis vaccine (inactivated, adsorbed)
Suspension for injection
Active immunization agent for the prevention of Japanese encephalitis
Valneva Austria GmbH
Campus Vienna Biocenter 3
A-1030 Vienna
Austria
Imported by:
Quality & Compliance Services Inc.
Mississauga
ON L5N 5R1
Manufactured for:
Valneva Canada Inc.
Kirkland
QC H9H 5B9
SUBMISSION CONTROL NO: 203520 DATE OF APPROVAL: MARCH 2, 2018
_ _
_Appendix I - Product Monograph Template - Schedule D _
_Page 2 of 57_
RECENT MAJOR LABEL CHANGES
Indication, Paediatrics
March, 2018
Dosage and Administration
March, 2018
Dosage forms, strenghts, composition and packaging
March, 2018
Warnings and Precautions, Special Populations
March, 2018
Special Handling Instructions
March, 2018
_ _
_Appendix I - Product Monograph Template - Schedule D _
_Page 3 of 57_
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES ......................................................................................
2
TABLE OF CONTENTS ...............................................................................................................
3
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 5
1
INDICATIONS
...................................................................................................................
5
1.1
Pediatrics
....................................................................................................................
5
2
CONTRAINDICATIONS
.................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................... 5
4
DOSAGE AND ADMINISTRATION
..............................................................................
6
4.1
Dosing Considerations
...............................................................................................
6
4.2